Skip to content
DataLookout
Menu

NCT07906145

A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety and Tolerability of QLS2416 Injection
Timeframe: Up to 24 weeks

Secondary (6)

Pharmacokinetic Profile of QLS2416
Anti-Drug Antibody
SLE Responder Index (SRI) and Other SLE Disease Activity Measures
RA Disease Activity Measures
pSS Disease Activity Measures
Show 1 moreShow less
SSc Disease Activity Measures

Arms and interventions

QLS2416Experimental

Dose Escalation Part: Participants with active SLE, RA, or pSS will receive single ascending subcutaneous doses of QLS2416 injection across 7 dose levels (0.025 mg to 6.0 mg). Dose Expansion Part: Participants with active SLE or SSc will receive multiple dosing of QLS2416 injection at 3 dose levels within the 4-week treatment period.

Drugs: QLS2416 Injection